Product Launch

RNS Number:0049J
Schering AG
20 March 2003

Schering to launch Finacea(TM) in the U.S.

Berlin, March 20, 2003 - Schering AG, Germany (FSE: SCH, NYSE: SHR) announced
today that its new dermatology product Finacea(TM) will be launched in the U.S.
market by early April 2003. Finacea(TM)(azelaic acid gel 15%) is Schering's new
topical treatment for rosacea, a dermatological disease that affects more than
13 million American adults.

"The introduction of Finacea(TM) in the U.S. market is an important milestone in
our strategy to globalize our Dermatology business", said Claus Zieler, Head of
Dermatology at Schering AG. "We are very pleased to offer patients who suffer
from rosacea a new and effective treatment option".

Simultaneously, Schering announced that its U.S. subsidiary, Berlex Laboratories
Inc., has entered into an agreement with the U.S. company Allergan, Inc. for the
co-promotion of Schering's Finacea(TM) in the U.S. market. The co-promotion
agreement calls for joint sales and marketing activities for Finacea(TM).

Additional information

Schering received marketing approval for Finacea(TM) from the U.S. Food and Drug
Administration (FDA) in December 2002. It was the first new therapeutic class
option to be approved in the U.S. for the treatment of rosacea in more than 10
years. Finacea(TM) is indicated for topical treatment of the inflammatory papules
and pustules of mild to moderate rosacea.

Additional data on Finacea(TM's) effectiveness will be presented at the venue of
the annual winter meeting of the American Academy of Dermatology (AAD) in San
Francisco (March 22-25, 2003).

Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology&Andrology, Diagnostics&
Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for
disabling diseases in the fields of the central nervous system, oncology and
cardiovascular system. As a global player with innovative products Schering AG
aims for leading positions in specialized markets worldwide. With in-house R&D
and supported by an excellent global network of external partners, Schering AG
is securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve the
quality of life: making medicine work

This press release has been published by Corporate Communication of Schering AG,
Berlin, Germany.

Your contacts at Corporate Communication:

Business: Dr Friedrich von Heyl, T: [phone];
[e-mail]

Investor Relations: Peter Vogt, T: [phone]; [e-mail]

Pharma: Dr Claudia Schmitt, T: [phone], [e-mail]

Your contacts in the U.S.:

Media Relations: Kimberley Jordan, T:[phone],
[e-mail]

Investor Relations: Joanne Marion, T: [phone], [e-mail]

Find additional information at: www.schering.de/eng



Certain statements in this press release that are neither reported financial
results nor other historical information are forward-looking statements,
including but not limited to, statements that are predictions of or indicate
future events, trends, plans or objectives. Undue reliance should not be placed
on such statements because, by their nature, they are subject to known and
unknown risks and uncertainties and can be affected by other factors that could
cause actual results and Schering AG's plans and objectives to differ materially
from those expressed or implied in the forward-looking statements. Certain
factors that may cause such differences are discussed in our Form 20-F and Form
6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG
undertakes no obligation to update publicly or revise any of these
forward-looking statements, whether to reflect new information or future events
or circumstances or otherwise.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
PRLXBLFLXXBXBBK